405 related articles for article (PubMed ID: 19638924)
1. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
Machens A; Lorenz K; Dralle H
Ann Surg; 2009 Aug; 250(2):305-10. PubMed ID: 19638924
[TBL] [Abstract][Full Text] [Related]
2. [Prophylactic thyroidectomy in children who are carriers of a multiple endocrine neoplasia type 2 mutation: description of 20 cases and recommendations based on the literature].
de Groot JW; Links TP; Rouwe CW; van der Wal JE; Hofstra RM; Plukker JT
Ned Tijdschr Geneeskd; 2006 Feb; 150(6):311-8. PubMed ID: 16503023
[TBL] [Abstract][Full Text] [Related]
3. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
4. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
[TBL] [Abstract][Full Text] [Related]
5. [Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree].
Zhao JQ; Guo L; Qi XP; Chen ZG; Wang KJ; Lou JL; Yu XH; Cheng J; Jin HY; Li XL; Ying RB; Zhang XN
Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(6):440-4. PubMed ID: 23660264
[TBL] [Abstract][Full Text] [Related]
6. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?
Niccoli-Sire P; Murat A; Rohmer V; Gibelin H; Chabrier G; Conte-Devolx B; Visset J; Ronceray J; Jaeck D; Henry JF; Proye C; Carnaille B; Kraimps JL;
Surgery; 2003 Dec; 134(6):1029-36; discussion 1036-7. PubMed ID: 14668737
[TBL] [Abstract][Full Text] [Related]
7. Early malignant progression of hereditary medullary thyroid cancer.
Machens A; Niccoli-Sire P; Hoegel J; Frank-Raue K; van Vroonhoven TJ; Roeher HD; Wahl RA; Lamesch P; Raue F; Conte-Devolx B; Dralle H;
N Engl J Med; 2003 Oct; 349(16):1517-25. PubMed ID: 14561794
[TBL] [Abstract][Full Text] [Related]
8. New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.
Frank-Raue K; Döhring J; Scheumann G; Rondot S; Lorenz A; Schulze E; Dralle H; Raue F; Leidig-Bruckner G
Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):550-3. PubMed ID: 20013610
[TBL] [Abstract][Full Text] [Related]
9. Medullary thyroid carcinoma.
Pacini F; Castagna MG; Cipri C; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
[TBL] [Abstract][Full Text] [Related]
10. Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791.
Frank-Raue K; Machens A; Scheuba C; Niederle B; Dralle H; Raue F;
Clin Endocrinol (Oxf); 2008 Aug; 69(2):259-63. PubMed ID: 18248648
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.
Skinner MA; Moley JA; Dilley WG; Owzar K; Debenedetti MK; Wells SA
N Engl J Med; 2005 Sep; 353(11):1105-13. PubMed ID: 16162881
[TBL] [Abstract][Full Text] [Related]
12. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer.
Machens A; Hoffmann F; Sekulla C; Dralle H
Endocr Relat Cancer; 2009 Dec; 16(4):1291-8. PubMed ID: 19726541
[TBL] [Abstract][Full Text] [Related]
13. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of "prophylactic therapy" for familial medullary thyroid cancer.
Schellhaas E; König C; Frank-Raue K; Buhr HJ; Hotz HG
Surgery; 2009 Nov; 146(5):906-12. PubMed ID: 19744457
[TBL] [Abstract][Full Text] [Related]
15. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities.
Machens A; Lorenz K; Dralle H
J Intern Med; 2009 Jul; 266(1):114-25. PubMed ID: 19522830
[TBL] [Abstract][Full Text] [Related]
16. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?
Calva D; O'Dorisio TM; Sue O'Dorisio M; Lal G; Sugg S; Weigel RJ; Howe JR
Ann Surg Oncol; 2009 Aug; 16(8):2237-44. PubMed ID: 19472011
[TBL] [Abstract][Full Text] [Related]
17. Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma?
Cardot-Bauters C; Leteurtre E; Leclerc L; Vantyghem MC; Do Cao C; Wemeau JL; d'Herbomez M; Carnaille B; Barbu V; Pinson S; Pigny P;
Clin Endocrinol (Oxf); 2008 Sep; 69(3):506-10. PubMed ID: 18331611
[TBL] [Abstract][Full Text] [Related]
18. Role of prophylactic thyroidectomy in RET 790 familial medullary thyroid carcinoma.
Bihan H; Baudin E; Meas T; Leboulleux S; Al Ghuzlan A; Hannoteaux V; Travagli JP; Valleur P; Guillausseau PJ; Cohen R;
Head Neck; 2012 Apr; 34(4):493-8. PubMed ID: 21688339
[TBL] [Abstract][Full Text] [Related]
19. Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E286-92. PubMed ID: 24297798
[TBL] [Abstract][Full Text] [Related]
20. Preventive thyroidectomy in patients with hereditary medullary thyroid carcinoma found heterozygote for mutant RET proto-oncogene.
Konstantinou E; Sapsakos Mariolis T; Fotis T; Mitsos A; Restos S; Mamoura K; Soultati A; Elefsiniotis I; Kapellakis G
Pediatr Endocrinol Rev; 2010 Dec; 8(2):108-13. PubMed ID: 21150841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
